News and communications

DASA seeks innovations to provide protection for land based assets from air attacks

• Updated: 17 April 2024

Batches of some products made by Legency Remedies Pvt Ltd have been found to contain a bacteria called Ralstonia pickettii (R. pickettii). All potentially affected batches are being recalled following an MHRA investigation.

• Updated: 5 April 2024

The MHRA has reviewed the latest evidence relating to the very rare risk of PRES and RCVS associated with medicines containing pseudoephedrine

• Updated: 20 February 2024

The Yellow Card Biobank will today start investigating a new group of medicines known as Direct Oral Anticoagulants

• Updated: 13 February 2024

No one should stop taking valproate without advice from their healthcare professional

• Updated: 31 January 2024

Do not stop your hypertriglyceridemia treatment without a discussion with your doctor

• Updated: 22 January 2024

Following a review of the effectiveness of current measures to reduce the risk of potentially long-term or irreversible side effects associated with fluoroquinolone antibiotics, the MHRA has introduced further restrictions t…

• Updated: 22 January 2024

The new safety measures being introduced in UK are for male and female patients

• Updated: 15 January 2024

The MHRA has reminded healthcare professionals prescribing aripiprazole to be alert to the known risk of patients developing addictive gambling, following a rise in the number of reports received in 2023

• Updated: 18 December 2023

Other effective medicines are available for epilepsy and bipolar disorder and valproate should only be used if these don’t work or aren’t suitable for an individual patient

• Updated: 28 November 2023

MHRA tells patients and healthcare professionals to stop using affected gels and retailers told to withdraw affected products.

• Updated: 24 November 2023

New measures strengthen the safe use of the acne drug isotretinoin for patients across the UK, following a patient-focused expert review

• Updated: 31 October 2023

No evidence of supply or harm to patients

• Updated: 18 October 2023

Patients to receive the latest valproate safety information with every pack, following changes to the Human Medicines Regulations, 2012

• Updated: 11 October 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has reinforced its safety guidance on the steps to take in anaphylaxis, after new figures obtained by the MHRA show more than 25,000 admissions to English hospit…

• Updated: 2 August 2023

The Medicines and Healthcare products Regulatory Agency (MHRA) has launched new guidance to highlight the latest safety advice on the steps to take during anaphylaxis. This new guidance includes an easy step-by-step guide on…

• Updated: 19 June 2023

Patients, or carers of patients, who carry Emerade 300 or 500 microgram adrenaline auto-injector pens should contact their GP and obtain a prescription for, and be supplied with an alternative brand. They should then return …

• Updated: 9 May 2023

The MHRA is reviewing the evidence relating to the very rare risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) associated with medicines containing pseudoeph…

• Updated: 23 February 2023

No one should stop taking valproate without advice from their healthcare professional

• Updated: 12 December 2022

Patients, carers and healthcare professionals with kits of the opioid overdose medicine Prenoxad Injection must visually check for the presence of two needles inside their kit. Any kits that do not have two needles should be…

• Updated: 10 November 2022